Results of 1-Year Growth Hormone (GH)-Releasing Hormone-(1-44) Treatment on Growth, Somatomedin-C, and 24-Hour GH Secretion in Six Children with Partial GH Deficiency
- 1 August 1987
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 65 (2) , 268-274
- https://doi.org/10.1210/jcem-65-2-268
Abstract
Six children with short stature and partial GH deficiency in response to two pharmacological tests received GHRH for 12 months (10 μg/kgday, sc) each evening. Twentyfour-hour GH secretion was studied before and after 3 and 12 months of treatment, and GHRH tests (2 μg/kg, iv) were done before and after 6 months of treatment. Plasma somatomedin-C was measured before and after 1.5, 3, 6, 9, and 12 months of treatment. Statural growth was measured at 3-month intervals. Mean growth velocity increased from 4.2 to 8.6 cm/yr, with a good result in five children and no response in the other. The growth response was substantial during the first 3 months. It was maintained during the following 6 months, and then decreased during the last 3 months. The peak plasma GH level in response to GHRH increased from 34.5 ± 14.2 (±sd) ng/mL before treatment to 47.8 ± 3.4 ng/mL after 6 months of treatment. Twenty-four-hour GH secretion increased in all parameters at 3 months (maximum peak, area under the curve, integrated concentration, and number of peaks) and at 12 months (with the exception of the maximum peak). Nycthemeral secretory profiles became normal, with reappearance of secretory pulses in two children, slight increases in three children, and no change in one child. Plasma somatomedin-C levels rose from 0.8 ± 0.3 U/mL before treatment to 2.0 ± 1.0 U/mL at 3 months, then decreased to 1.3 ± 0.6 U/mL at 12 months. These results indicate that GHRH administered by sc injection for a 1-yr period stimulated growth and GH secretion. However, a decrease in activity was noted during the last 3 months of treatment. Tests for anti-GHRH antibodies were positive in the only child who did not respond to treatment.Keywords
This publication has 13 references indexed in Scilit:
- Effects of Intravenous, Subcutaneous, and Intranasal Administration of Growth Hormone (GH)-Releasing Hormone-40 on Serum GH Concentrations in Normal Men*Journal of Clinical Endocrinology & Metabolism, 1985
- Effects of Pulsatile Administration of Growth Hormone (GH)-Releasing Hormone on Short Term Linear Growth in Children with GH Deficiency*Journal of Clinical Endocrinology & Metabolism, 1985
- Growth Hormone Responses to Continuous Infusions of Growth Hormone-Releasing Hormone*Journal of Clinical Endocrinology & Metabolism, 1985
- Evidence for a Limited Growth Hormone (GH)-Releasing Hormone (GHRH)-Releasable Quantity of GH: Effects of 6-Hour Infusions of GHRH on GH Secretion in Normal Man*Journal of Clinical Endocrinology & Metabolism, 1985
- Growth Hormone Release in Response to Human Pancreatic Tumor Growth Hormone-Releasing Hormone-40 in Children with Short Stature*Journal of Clinical Endocrinology & Metabolism, 1984
- Dose-Response Relationships for the Effects of Growth Hormone-Releasing Factor-(1–44)-NH2in Young Adult Men and WomenJournal of Clinical Endocrinology & Metabolism, 1984
- Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation.Journal of Clinical Investigation, 1984
- Plasma Growth Hormone (GH) Response to GH-Releasing Factor in Normal Children with Short Stature and Patients with Pituitary Dwarfism*Journal of Clinical Endocrinology & Metabolism, 1984
- Synthetic hpGRF 1–40 stimulates growth hormone and inhibits prolactin secretion in normal children and children with isolated growth hormone deficiencyPeptides, 1983
- Growth Hormone-Releasing Factor from a Human Pancreatic Tumor That Caused AcromegalyScience, 1982